Selected characteristics of the patients and associations with VTE and OS
| Characteristic . | Number (632 total) . | % of total . |
|---|---|---|
| Age ≥60 y | 469 | 74.2 |
| Male sex | 326 | 51.6 |
| Race | ||
| White | 561 | 88.8 |
| Black | 54 | 8.5 |
| Other/unknown | 17 | 2.7 |
| Ethnicity | ||
| Non-Hispanic | 361 | 57.1 |
| Hispanic | 252 | 39.9 |
| Unknown | 19 | 3.0 |
| Tobacco history | ||
| None/never used | 138 | 21.8 |
| Any current/prior use | 483 | 76.4 |
| Baseline WBC ≥11 × 109/L | 151 | 23.9 |
| Baseline Hb <10 g/dL | 64 | 10.1 |
| Baseline Plt ≥350 × 109/L | 174 | 27.5 |
| BMI, kg/m2 | ||
| <18.5 | 37 | 5.9 |
| 18.5-24.9 | 240 | 38.0 |
| ≥25-25.9 | 354 | 56.0 |
| KS | ||
| 1-2 | 534 | 84.5 |
| 3-4 | 97 | 15.3 |
| Lung cancer type | ||
| AC | 389 | 61.6 |
| SCC | 108 | 17.1 |
| NSCLC, NOS | 34 | 5.4 |
| SCLC | 94 | 14.9 |
| Unknown/other | 7 | 1.1 |
| AJCC stage | ||
| I-II | 102 | 16.1 |
| III-IV | 490 | 77.5 |
| Unknown | 40 | 6.3 |
| Therapy type | ||
| Chemotherapy | 223 | 35.3 |
| Chemoimmunotherapy | 297 | 47 |
| Targeted therapy | 77 | 12.2 |
| Radiation therapy | 283 | 44.8 |
| Surgery | 158 | 25.0 |
| VTE | ||
| Before therapy (90 d) | 20 | 3.1 |
| After initiating therapy | 44 | 6.9 |
| Yes (total) | 64 | 10.1 |
| Vital status | ||
| Alive at 6 mo | 549 | 86.9 |
| Alive at 12 mo | 466 | 73.7 |
| Characteristic . | Number (632 total) . | % of total . |
|---|---|---|
| Age ≥60 y | 469 | 74.2 |
| Male sex | 326 | 51.6 |
| Race | ||
| White | 561 | 88.8 |
| Black | 54 | 8.5 |
| Other/unknown | 17 | 2.7 |
| Ethnicity | ||
| Non-Hispanic | 361 | 57.1 |
| Hispanic | 252 | 39.9 |
| Unknown | 19 | 3.0 |
| Tobacco history | ||
| None/never used | 138 | 21.8 |
| Any current/prior use | 483 | 76.4 |
| Baseline WBC ≥11 × 109/L | 151 | 23.9 |
| Baseline Hb <10 g/dL | 64 | 10.1 |
| Baseline Plt ≥350 × 109/L | 174 | 27.5 |
| BMI, kg/m2 | ||
| <18.5 | 37 | 5.9 |
| 18.5-24.9 | 240 | 38.0 |
| ≥25-25.9 | 354 | 56.0 |
| KS | ||
| 1-2 | 534 | 84.5 |
| 3-4 | 97 | 15.3 |
| Lung cancer type | ||
| AC | 389 | 61.6 |
| SCC | 108 | 17.1 |
| NSCLC, NOS | 34 | 5.4 |
| SCLC | 94 | 14.9 |
| Unknown/other | 7 | 1.1 |
| AJCC stage | ||
| I-II | 102 | 16.1 |
| III-IV | 490 | 77.5 |
| Unknown | 40 | 6.3 |
| Therapy type | ||
| Chemotherapy | 223 | 35.3 |
| Chemoimmunotherapy | 297 | 47 |
| Targeted therapy | 77 | 12.2 |
| Radiation therapy | 283 | 44.8 |
| Surgery | 158 | 25.0 |
| VTE | ||
| Before therapy (90 d) | 20 | 3.1 |
| After initiating therapy | 44 | 6.9 |
| Yes (total) | 64 | 10.1 |
| Vital status | ||
| Alive at 6 mo | 549 | 86.9 |
| Alive at 12 mo | 466 | 73.7 |
Race and ethnic group were reported by the patient. Patients who received radiation therapy and surgery could have received other therapies. Boldface type indicates significance at P <.05.
AC, adenocarcinoma; AJCC, American Joint Committee on Cancer; NOS, not otherwise specified; SCC, squamous cell carcinoma.